Literature DB >> 3965856

Cerebrovascular complications in patients with cancer.

F Graus, L R Rogers, J B Posner.   

Abstract

In an autopsy study of patients with cancer, 14.6% had pathologic evidence of cerebrovascular disease (CVD), and in 7.4% clinical symptoms of CVD had been present in life. The usual risk factors for CVD were overshadowed by pathophysiologic abnormalities related to the neoplasm, including direct effects of the tumor, coagulation disorders, infections and diagnostic or therapeutic procedures. In patients with leukemia, hemorrhages (72.4%) were much more common than ischemic infarcts. In lymphoma patients, the incidence of cerebral bleeding was lower (36.3%). In both groups, the leading causes of ischemic infarction were septic thrombi and intravascular coagulation. In patients with carcinoma, cerebral infarctions (54.1%) were more frequent than hemorrhages. NBTE (18.5%) and intravascular coagulation (9.6%) were the most common etiologies. Hemorrhages other than intratumoral bleeding in patients with melanoma or germ cell tumors were unusual. The clinical presentation of CVD in patients with cancer is more often a diffuse encephalopathy, with or without localizing signs, than the typical acute onset of a focal deficit. This was particularly true with intravascular coagulation, septic infarction and subdural hematoma. Our study suggests that by knowing the clinical setting, neurologic features and laboratory findings, one can, in many instances, make an accurate clinical diagnosis that, in some cases, leads to effective treatment.

Entities:  

Mesh:

Year:  1985        PMID: 3965856     DOI: 10.1097/00005792-198501000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  117 in total

1.  Cerebral vasculopathy and multiple infarctions in a woman with carcinomatous meningitis while on treatment with intrathecal methotrexate.

Authors:  S Kastenbauer; M Wiesmann; H W Pfister
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Bronchogenic adenocarcinoma presenting as a synchronous solitary lytic skull lesion with ischaemic stroke--case report and literature review.

Authors:  David O'Connell; Chandrasekaran Kaliaperumal; Gerald Wyse; Julie McCarthy; Aisling Ryan
Journal:  BMJ Case Rep       Date:  2011-12-20

Review 3.  Headache in patients with cancer.

Authors:  Samuel A Goldlust; Jerome J Graber; Dana F Bossert; Edward K Avila
Journal:  Curr Pain Headache Rep       Date:  2010-12

Review 4.  Stroke in cancer patients.

Authors:  Teri Nguyen; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 5.  Neurologic complications of cancer and its treatment.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

6.  Predictors of unknown cancer in patients with ischemic stroke.

Authors:  Sonia Quintas; Jacobo Rogado; Pedro Gullón; Vilma Pacheco-Barcia; Julio Dotor García-Soto; Gemma Reig-Roselló; Rebeca Mondéjar; Ramón Colomer; Jose Vivancos
Journal:  J Neurooncol       Date:  2018-01-08       Impact factor: 4.130

7.  Malignancy and hypercoagulability: a two-way association revisited.

Authors:  Elie G Aoun; Khaled M Musallam; Mohamad Abou-Ghazal; Ali T Taher
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

8.  Ischaemic myelopathy secondary to disseminated intravascular coagulation in AIDS.

Authors:  G Fenelon; F Gray; F Scaravilli; F Mahieux; R Gherardi; P Chemouilli; A Guillard
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

9.  Aleukaemic leukostasis in a case of large cell non-Hodgkin's lymphoma: report of a case with a distinctive central nervous system involvement.

Authors:  S Jain; D Kotasek; P C Blumbergs; R E Sage
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

10.  Cerebral achromatopsia as a presentation of Trousseau's syndrome.

Authors:  R W Orrell; M James-Galton; J M Stevens; M N Rossor
Journal:  Postgrad Med J       Date:  1995-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.